Save lives, save time, save your community.
Faster, more confident lung readings.
Where is your organization on your lung cancer detection journey? Choose the question that fits your needs, find more resources and see how we can help!
How to: Get Going
“Where do I start with lung cancer?
There’s just so much to think about!”
How to: Get Growing
We have started an incidental nodule program, but the screening guidelines keep changing, and there’s so much volume to read all those CT studies!
How to: Get Flowing
We’re running both an incidental nodule program and a screening program…are there any resources for us?
At Riverain Technologies, we are on a mission to save lives through the early detection, diagnosis, and management of lung disease. No matter where in the lung cancer detection journey you are, check out these resources – we have something for everyone!
Lung Cancer Programs: Go, Grow and Flow
“Where do I start with lung cancer? There’s just so much to think about!”
Let’s start with statistics and language:
- Did you know? Lung Cancer detected in the early stages is 10x more curable than late stage lung cancer. Guess what? Unfortunately, almost half of lung cancer is detected in the later stages. During CT studies ordered for other reasons, incidental nodules can provide a valuable early detection tool. Learn more about how customers use our software to find and follow lung abnormalities.
- Based on your population (age, risk, industries) are you more concerned about screening or finding incidental nodules? The American Lung Association has some fantastic resources to identify whether environmental, occupational or social drivers are most important in your community. Knowing the source of risk can help you decide where to focus first. Learn more from this research.
- Since many incidental nodules are benign, they can often be seen as a nuisance. The need for follow up can cause anxiety for patients while nodules are further characterized through imaging or biopsy. On the other hand, accurate detection and sizing can support care coordination and patient management within your community. Using consensus guidelines can support and streamline management of patients with incidental nodules.
- The Fleishner Society Guidelines are the widely accepted standard of care for the management and tracking of lung nodules. Reliable measurement and characterization of both solid and part-solid nodules is an important part of these guidelines. Read the guidelines.
“We have started an incidental nodule program, but since screening guidelines keep changing, and there’s so much volume to read all those studies, screening seems like too much work for our organization. Plus, screening reimbursement makes running a screening program margin dilutive… why would I do it?”
According to Healthy People 2030, only about 5% of Americans who should be screened for lung cancer actually get screened and tracked.
- Lung cancer screening guidelines changed many times over the last 10 years leading to confusion and frustration. These changes were driven by changes and challenges in lung imaging and reading methods. In May 2021, the United States Preventive Services Task Force (USPSTF) published new guidelines based on clinical findings that demonstrated the clear value of screening in saving lives. Summary? Annual screening is recommended for people aged 50-80 with a 20 pack-year smoking habit who have quit within the last 15 years.
- Even better news than clear guidelines? Clear and improving reimbursement for screening by health systems. In November 2021, the Centers for Medicare and Medicaid Services recommended an increase to reimbursement for low dose CT specifically for lung cancer screening. The 37% increase is driven by reclassification of CPT code 71271 into APC 5522: Imaging without Contrast and is in alignment with the demonstrated need to screen to detect lung cancer earlier.
“We’re running both an incidental nodule program and a screening program…are there any resources for us?”
Congratulations! You’re already well aware of the opportunities for community care that are presented by lung cancer screening. We would love to connect with you to help your radiology and multidisciplinary teams see the power of ClearRead CT in the following areas:
Still have questions? We would love to connect! Request a demonstration.